title: Management of thyroid carcinoma with radioactive 131I.
abstract: OBJECTIVE
  To evaluate the role of radioactive 131I in the management of patients with well differentiated carcinoma of the thyroid.
  
  
  METHODS
  Between 1965 and 1995, a total of 117 patients with well-differentiated carcinoma of the thyroid underwent either lobectomy or thyroidectomy followed by 100-150 mCi of 131I.
  
  
  RESULTS
  With a median follow-up of 8 years, only four patients (3%) developed a recurrence of their disease. The 5-year actuarial survival was 97% with a 10-year survival of 91%. There were no severe side effects noted after 131I therapy.
  
  
  CONCLUSIONS
  Radioactive 131I is a safe and effective procedure for the majority of patients with well-differentiated thyroid carcinoma. We currently recommend that all patients undergo a subtotal or total thyroidectomy followed by 131I thyroid scanning approximately 4 weeks after surgery. If the thyroid scan shows no residual uptake and all disease is confined to the thyroid, we recommend following patients with annual thyroid scans and serum thyroglobulin levels. If there is any residual uptake detected in the neck or if the tumor extends beyond the thyroid, we recommend routine thyroid ablation of 100-150 mCi of radioactive 131I.
authors.affiliation: Department of Radiation Oncology, Florida Radiation Oncology Group, Baptist Medical Center, Jacksonville, USA.
authors.forename: S B
authors.initials: SB
authors.lastname: Paryani
authors.forename: R J
authors.initials: RJ
authors.lastname: Chobe
authors.forename: W
authors.initials: W
authors.lastname: Scott
authors.forename: J
authors.initials: J
authors.lastname: Wells
authors.forename: D
authors.initials: D
authors.lastname: Johnson
authors.forename: A
authors.initials: A
authors.lastname: Kuruvilla
authors.forename: S
authors.initials: S
authors.lastname: Schoeppel
authors.forename: A
authors.initials: A
authors.lastname: Deshmukh
authors.forename: R
authors.initials: R
authors.lastname: Miller
authors.forename: L
authors.initials: L
authors.lastname: Dajani
authors.forename: C T
authors.initials: CT
authors.lastname: Montgomery
authors.forename: E
authors.initials: E
authors.lastname: Puestow
authors.forename: J
authors.initials: J
authors.lastname: Purcell
authors.forename: M
authors.initials: M
authors.lastname: Roura
authors.forename: D
authors.initials: D
authors.lastname: Sutton
authors.forename: R
authors.initials: R
authors.lastname: Mallett
authors.forename: J
authors.initials: J
authors.lastname: Peer
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002277:Carcinoma / Q000378:metabolism / Q000532:radiotherapy* / Q000601:surgery; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007455:Iodine / Q000378:metabolism; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D013964:Thyroid Neoplasms / Q000378:metabolism / Q000532:radiotherapy* / Q000601:surgery
chemical_list: D007457:Iodine Radioisotopes; D007455:Iodine